AstraZeneca Overview
- Status
- Public
- Employees
- 70,600
- Stock Symbol
- AZN
- Investments
- 66
- Share Price
- $106.52
- (As of Wednesday Closing)
AstraZeneca General Information
Description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Contact Information
Website
Formerly Known As
Zeneca Group
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Stock Exchange
LON
Primary Office
- 1 Francis Crick Avenue
- Cambridge Biomedical Campus
- Cambridge CB2 0AA
- England, United Kingdom
+44 020 0000 0000
AstraZeneca Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $106.52 | $104.01 | $72.78 - $127.21 | $136B | 1.31B | 2.09M | $1.90 |
AstraZeneca Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 157,814,810 | 145,733,740 | 112,692,471 | 101,489,615 |
| Revenue | 25,871,000 | 24,384,000 | 22,090,000 | 22,465,000 |
| EBITDA | 7,011,000 | 5,380,000 | 6,006,000 | 5,941,000 |
| Net Income | 2,497,000 | 1,335,000 | 2,155,000 | 3,001,000 |
| Total Assets | 64,112,000 | 61,377,000 | 60,651,000 | 63,354,000 |
| Total Debt | 22,339,000 | 18,227,000 | 19,113,000 | 17,807,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AstraZeneca Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore AstraZeneca‘s full profile, request access.
Request a free trialAstraZeneca Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells br
Pharmaceuticals
Cambridge, United Kingdom
70,600
As of 2019
000
00000000
000
00000000
e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur s
000000000000000
Brentford, United Kingdom
00000
As of 0000
00000000000
0000000
didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
0000000000000
Gaithersburg, MD
000
As of 0000
00000
000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAstraZeneca Competitors (49)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | Corporation | Brentford, United Kingdom | 00000 | 00000000000 | ||
| 0000000 | Corporation | Gaithersburg, MD | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporation | Montreal, Canada | 000 | 00000 | 00000000 | 00000 |
| 00000000 | Corporation | Richmond, VA | 000 | 00000 | 0000 | 00000 |
| 00000 | Corporation | Tokyo, Japan | 00000 | 0000 |
AstraZeneca Executive Team (79)
AstraZeneca Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 | Self | Board Member | 000 0000 |
| 000000000 000000 | Self | Board Member | 000 0000 |
| 000000 000000000 | Self | Board Member | 000 0000 |
| 0000 000000000 | Self | Non-Executive Chairman of the Board, Chairman of the Nomination and Governance Committee & Member of the Remuneration Committee | 000 0000 |
| 0000 0000000 | AstraZeneca | Executive Director & Chief Financial Officer | 000 0000 |
AstraZeneca Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAstraZeneca Investments & Acquisitions (66)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000000000 | 17-Sep-2020 | 000000000 00000 00 | Buildings and Property | 0000000 00000000 00.0 | |
| 0000000 | 11-Sep-2020 | 00000 00000 00 | 00.000 | Other Devices and Supplies | |
| 000000000 (0000000 | 27-Jan-2020 | 000000000 00000 00 | Buildings and Property | 0000000 00000000 00.0 | |
| 0000000 000000 000 | 30-Sep-2019 | 000000000 00000 00 | 0000 | Buildings and Property | |
| ADC Therapeutics | 12-Jun-2019 | Later Stage VC | 00000 | Drug Discovery |
AstraZeneca Subsidiaries (11)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Acerta Pharma | Drug Discovery | Oss, Netherlands | 2012 |
| 00 000000 | Drug Discovery | Coppell, TX | 0000 |
| 00000 000000000000 | Therapeutic Devices | Redwood City, CA | 0000 |
| 0000000 000000 | Pharmaceuticals | Tokyo, Japan | 0000 |
| 0000 00000000 | Biotechnology | Waltham, MA | 0000 |
AstraZeneca Exits (13)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 000000000 | 25-Apr-2018 | 00000 00000 00 | 0000 | Completed |
|
| 00000 000 | 13-Mar-2018 | 00000 00000 00 | 00000 | Completed |
|
| 0000000 0000000000 | 07-Sep-2016 | 00000 00000 00 | 00000 | Completed |
|
| 00000000 000000000 | 17-Feb-2016 | 00000 00000 00 | 000.00 | Completed |
|
| Alvesco, Omnaris and Zetonna (Asthma Medication) | 16-Dec-2015 | Corporate Asset Purchase | Completed |